Glucagon fragment: lab tool for studying blood-sugar regulation (glucagon precursor [53-68])

What this is

The glucagon precursor [53–68] peptide is a 16-residue fragment — HSQGTFTSDYSKYLDS — that corresponds to the first 16 amino acids of the 29-residue glucagon hormone. Glucagon is the pancreatic alpha-cell hormone that raises blood sugar in response to hypoglycemia, acting through the glucagon receptor (GCGR), a class B G-protein-coupled receptor on liver cells. This shorter fragment has been catalogued as a distinct entity in structural comparisons of the glucagon peptide family. It is a synthetic research tool used to study GCGR recognition and the structural requirements for binding within the class B GPCR field; it is not an approved drug or therapeutic.

What it does

Full-length glucagon signals through GCGR to stimulate hepatic glycogenolysis and gluconeogenesis, rapidly raising blood glucose. The 16-residue N-terminal region encoded by this fragment contains the glucagon pharmacophore — the segment most critical for receptor engagement in class B GPCRs. Structural studies of the full-length GCGR bound to glucagon have defined how this N-terminal region docks into the transmembrane bundle of the receptor (Zhang and colleagues, Nature 2017; Qiao and colleagues, Science 2020). This fragment therefore serves as a minimal-sequence reference in studies characterising what portion of glucagon is required for GCGR activation or binding.

The GCGR itself has been shown to be required for the liver's adaptive response to fasting: mice lacking functional GCGR cannot sustain normal hepatic glucose output during food restriction (Longuet and colleagues, Cell Metabolism 2008).

Evidence

• Human: No clinical trials have been reported for this specific 16-residue fragment. Evidence is restricted to its appearance in structural and biochemical comparisons of glucagon-family peptides.
• Animal: The parent receptor (GCGR) has been studied in fasting-physiology models; loss of GCGR abolishes the normal metabolic adaptation to fasting in mice (Longuet and colleagues, Cell Metabolism 2008). No published in vivo data specifically for this fragment were identified in the dossier.
• In vitro: The fragment sequence appears in peptide-sequence comparison tables used in structural and biochemical studies of the glucagon peptide family. No binding affinity measurements (Ki, IC50) for this specific 16-mer against GCGR were identified in the dossier.

Mechanism

GCGR is a class B GPCR whose extracellular domain (ECD) acts as an intrinsic negative regulator of receptor activity: structural studies showed that the ECD can occlude the ligand-binding site, and antibody blockade of the ECD inhibits receptor activation (Koth and colleagues, PNAS 2012). Crystal and cryo-EM structures of full-length GCGR have been determined in complex with glucagon and with both Gs and Gi heterotrimeric G proteins, establishing the molecular basis for how glucagon's N-terminal region engages the transmembrane cavity while the mid-region contacts the ECD (Zhang and colleagues, Nature 2017; Qiao and colleagues, Science 2020). The sequence HSQGTFTSDYSKYLDS is this N-terminal engagement region.

The glucagon receptor shares partial sequence homology with GLP-1R in its transmembrane domain, and structural determinants of binding show meaningful divergence between the two receptors — a distinction that has informed the design of selective versus dual-agonist peptides in the incretin drug class (Yang and colleagues, Journal of Biological Chemistry 2016).

The human GCGR was first cloned and expressed in 1994 (Macneil and colleagues, Biochemical and Biophysical Research Communications 1994). Loss-of-function mutations in GCGR cause a rare endocrine disorder; a pediatric case of biallelic GCGR mutations presenting with elevated arginine on newborn screening has been documented (Li and colleagues, Molecular Genetics and Metabolism Reports 2018).

Related peptides

• Glucagon — the full 29-residue parent hormone from which this fragment is derived; FDA-approved for emergency hypoglycemia rescue and as a diagnostic smooth-muscle relaxant.
• See also: retatrutide, survodutide, mazdutide — investigational dual and triple agonists incorporating GCGR agonism alongside GLP-1R and/or GIPR activity (cards not yet linked).